Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASC40
- Development stage
- Preclinical
- Lead developer
- Ascletis Pharma
- Modality
- Peptides
- Administration
- Oral
01
Overview
ASC40 is a peptide-based agonist of the glucagon-like peptide-1 receptor (GLP-1R) being developed by Ascletis Pharmaceuticals for the treatment of sleep disorders. While the code name ASC40 is also associated with denifanstat, a small molecule fatty acid synthase (FASN) inhibitor in the company's pipeline for metabolic conditions, this specific peptide candidate is uniquely positioned for neurological indications. GLP-1R agonists are increasingly recognized for their neuroregulatory potential, and ASC40 is being investigated for its ability to modulate pathways involved in sleep-wake cycles and related sleep pathologies. The drug is currently in early-stage development.
02
Targets
FASN (Fatty acid synthase)
Beyond the preview
Go deeper on ASC40.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASC40.